top of page
Laurus Labs


Rs. 512

Buy on dips


Laurus Labs

Result Update (Q4 FY20)

May 3, 2020 at 5:51:50 PM

Quick Update

Laurus Labs reported a consecutive beat with best-ever topline of Rs. 839 cr up by 15% Q-o-Q with an EBITDA of Rs. 191 cr and an EBITDA margin of 22.9%. PAT came in at Rs. 110 cr up by 50% from Rs. 73 cr reported in Q3 FY20. Laurus Labs also declared a final dividend of Rs. 1 / share apart from the interim dividend of Rs. 1.5 / share declared in March 2020. With a consistent robust performance over the past few quarters and an increase in EBITDA share from high margin businesses (synthesis and formulations) laurus labs has embarked upon a good growth trajectory. We expect formulation segment to further aid EBITDA margins led by higher capacities. Laurus labs has also filed for 26 ANDA's with 6 final approvals and 5 tentative approvals in place. Given the current valuations we assign an Accumulate rating to the stock and opine to buy on dips.

Download the full update

Other recent updates

bottom of page